TheraRadar
← Back
Data updated: May 24, 2026

Novo Nordisk

NVO Big Pharma
MetabolicOncologyImmunology Execution: Excellent

Danish pharma dominating diabetes and obesity markets with Ozempic, Wegovy, and insulin portfolio. World leader in GLP-1 therapies.

$35.7B
Revenue (2024)
$420.0B
Market Cap
-
Trials
4
New Drugs (2yr)
Modality:
7 Small Molecules 20 Biologics
Novel Drugs (2017-2024):
4 Novel Approvals 1 First-in-Class 2 Orphan Drug 1 Breakthrough

Novo Nordisk at a Glance

  • Strong track record with 84% execution quality across 709 trials
  • Fast trial execution (12 months median completion)

Upcoming FDA Decisions

Full Calendar →
Oct 18, 2026 — CagriSema (cagrilintide + semaglutide)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

AWIQLI FLEXTOUCH BLA
2026-03-26
insulin icodec
1 INDICATIONS AND USAGE Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Awiqli is a long-acting human insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 )
WEGOVY NDA
2025-12-22
semaglutide
1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity. o Adults with overweight in the presence of at least one weight-related comorbid condition. • For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies ( 14.4 )] . Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) event
ALHEMO BLA
2025-07-31
concizumab
Hemophilia A
ALHEMO BLA
2024-12-20
concizumab-mtci
Hemophilia A

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Metabolic 90%
12 drugs Phase 3: 198 Phase 2: 37 Phase 1: 299
Oncology 3%
0 drugs Phase 3: 7 Phase 2: 5 Phase 1: 9
Immunology 3%
0 drugs Phase 3: 2 Phase 2: 8 Phase 1: 12
Cardiovascular 2%
0 drugs Phase 3: 5 Phase 2: 3 Phase 1: 7
Infectious Disease 1%
0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 6

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

213
Phase 3
56
Phase 2
333
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q2 2026
Cagrilintide
Diabetes Mellitus, Type 2
Estimated · fresh NCT06534411
Q2 2026
Ziltivekimab B
Cardiovascular Risk
Estimated · fresh NCT05021835
Q2 2026
Oral semaglutide
Type 2 Diabetes
Estimated · fresh NCT07271251
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OZEMPIC leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 204/246 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges